No Data
No Data
No Data
No Data
No Data
NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma)
Yahoo FinanceApr 26 04:12 ET
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Innate Pharma SA (OtherIPHYF) and Neumora Therapeutics, Inc. (NMRA)
TipRanksApr 17 04:10 ET
Innate Pharma's NK Cell Engager Enters Phase 2 Trials
TipRanksApr 15 21:00 ET
Sezary Syndrome Pipeline Insights 2024, Featuring Major Players 4SC, Seagen, Merck Sharp & Dohme, Innate Pharma, Trillium Therapeutics and Secura Bio
Yahoo FinanceApr 15 10:07 ET
Express News | Innate Pharma Advances Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing To Phase 2 For Blood Cancer Patients
Moomoo 24/7Apr 15 01:47 ET
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") will hold its Annual General Meeting of Shareholders ("AGM") at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de
BusinesswireApr 15 01:00 ET
No Data
No Data